Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. - Wikidata - wikimedia - TriplyDB

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.

http://www.wikidata.org/entity/Q30398715

about

Antibody-Based Strategies to Prevent and Treat Influenza The epidemiological and public health research response to 2009 pandemic influenza A(H1N1): experiences from Hong Kong The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis The Therapeutic Effect of Pamidronate on Lethal Avian Influenza A H7N9 Virus Infected Humanized Mice Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role.Rapid Generation of Human-Like Neutralizing Monoclonal Antibodies in Urgent Preparedness for Influenza Pandemics and Virulent Infectious Diseases.Avian influenza A H5N1 virus: a continuous threat to humans.Two years after pandemic influenza A/2009/H1N1: what have we learned?A review of treatment modalities for Middle East Respiratory Syndrome.Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol Clinical care for severe influenza and other severe illness in resource-limited settings: the need for evidence and guidelines.Evaluation of neutralizing efficacy of monoclonal antibodies specific for 2009 pandemic H1N1 influenza A virus in vitro and in vivo.Adjunctive therapies and immunomodulating agents for severe influenza.Serological response of patients with influenza A (H1N1) pdm09-associated pneumonia: an observational study.Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia.Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice Continuing challenges in influenza.Passive broad-spectrum influenza immunoprophylaxis A broadly neutralizing human monoclonal antibody is effective against H7N9.INSIGHT FLU005: An Anti-Influenza Virus Hyperimmune Intravenous Immunoglobulin Pilot Study.Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1N1 2009 influenza.Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection.Comparison of immunoglobulin G subclass concentrations in severe community-acquired pneumonia and severe pandemic 2009 influenza A (H1N1) infection.The Management of the 2009 pandemic Influenza A H1N1 virus infection Passive immune neutralization strategies for prevention and control of influenza A infections.Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem.Identification of dominant antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin antigen of pandemic H1N1 influenza virus.Newer influenza antivirals, biotherapeutics and combinations.Fc functional antibodies in humans with severe H7N9 and seasonal influenza Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease Assessing mathematical models of influenza infections using features of the immune response.Using convalescent whole blood or plasma as passive immune therapy for the global war against Ebola.How to approach and treat viral infections in ICU patients Severe acute respiratory syndrome (SARS): lessons learnt in Hong Kong Clinical, virological and immunological features from patients infected with re-emergent avian-origin human H7N9 influenza disease of varying severity in Guangdong province A study in scarlet-convalescent plasma for severe influenza*.Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus.Feasibility of a randomized controlled trial to assess treatment of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection in Saudi Arabia: a survey of physicians.Suboptimal Humoral Immune Response against Influenza A(H7N9) Virus Is Related to Its Internal Genes.The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome.

P2860

Q26798520-A2ED5A38-8FD4-44A4-B6EE-94CC7009844E Q27000773-BBB18F77-E322-4D6B-AD78-3B3583AED940 Q27001157-09245389-0DD6-4250-87C5-C88696562E02 Q27322928-F2074044-22C9-4CA1-85FA-D04DD9914783 Q30145641-CB80F602-A947-4DF8-8325-DFA279B99A7C Q30222441-8E77DEA4-67C8-4E8E-8C88-BE0E5EED14AD Q30224462-300E19E4-097B-4FDA-A5E7-83BE03160BE0 Q30224656-AD5F6841-102F-4B81-8C45-FD2E4AE08174 Q30248209-248849E5-81BE-4619-AECB-E8999FFDAC20 Q30277992-22533BA6-01A7-46E9-94CA-16E491DB99D2 Q30353609-1C894044-83B9-4B92-990C-CBBFD54999FC Q30353823-D0769B01-9C61-435D-8AA8-758799E6E595 Q30355446-43A5D859-A4C7-406F-B6E0-4CAAAB3423EE Q30356492-AE397737-2D67-4DC7-8B5B-F8ADB905C307 Q30356651-40251E2C-9A2D-4310-8F6A-9BEC8B569B51 Q30361437-1F912B23-E0A9-4EAC-B8A4-CA29A9F46194 Q30363190-BD486A7E-D0A1-4DA4-8357-DEB558E9F244 Q30367936-00172989-7F41-4B15-B367-6EF79D92649C Q30378035-2BA89AD0-FB6C-40E4-A3A7-4947ED86F526 Q30379199-D6BEE98E-B562-4437-AEB6-CDE260A1D78A Q30400817-97C19385-C87E-42B7-ACBD-9E34ABD592C6 Q30401056-49FEF3AC-5047-4EF9-8113-78A2110BE5EC Q30411633-B4DC5A3E-089C-4105-80D2-86F4207D0F0E Q30412410-864EA178-442A-4E88-9B80-04876727AB0D Q30413158-90487A7C-5046-4B86-BF27-3C5080AC16C9 Q30416784-77C49C6C-8630-4E4A-82AC-94E66C4F7FB9 Q30428189-35A3AD62-D1D8-4B7C-8810-1AED7CB54A88 Q30456363-EB47A9D9-C807-4F0F-94DE-02DB72AAADA7 Q33877811-C921866A-6897-4A66-AD69-D20C43CD4630 Q34468689-22EF22C4-C7E6-4413-8A80-D8F480C4623F Q34611749-6A5062EC-5DCC-444A-A194-083E3EEC29DA Q34762871-0A4CD260-185D-4A30-9073-CA9BF4E7E91A Q34894660-48A3AA9F-5586-4DCD-B51B-D92C31ABE66C Q34974298-58369CA7-4ED3-4C92-ACDD-773542581FB3 Q35130199-27CC002E-5EBE-43D5-94FF-29A8CAEA65EC Q35779683-41C7704C-FE97-44FF-9BD2-1BBD7376712C Q35989939-C94643F9-DC7E-45E4-9042-73BEFD653600 Q36074163-109BE9D2-541F-4E01-84C1-F8DAC394D269 Q36316782-89DED26B-F289-4C04-B2B4-1FB578B6D269 Q36730084-CC4E1E35-BD04-4A9E-9CFD-18AA7E8B0C13

P2860

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.

http://www.wikidata.org/entity/Q30398715

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Convalescent plasma treatment ...... A (H1N1) 2009 virus infection.

@ast

Convalescent plasma treatment ...... A (H1N1) 2009 virus infection.

@en

type

label

Convalescent plasma treatment ...... A (H1N1) 2009 virus infection.

@ast

Convalescent plasma treatment ...... A (H1N1) 2009 virus infection.

@en

prefLabel

Convalescent plasma treatment ...... A (H1N1) 2009 virus infection.

@ast

Convalescent plasma treatment ...... A (H1N1) 2009 virus infection.

@en

P1433

Q30398715-BEEE5477-0156-4D59-AE44-2FFF6ABE67F8

P1476

Q30398715-778CCC22-B7AC-4750-9B13-F67A717C7952

P2093

Q30398715-1107D6EF-3A0E-4C6A-B5CC-51FD24878F0A

Q30398715-260F9717-40EF-4394-87BD-ABF6425A618E

Q30398715-508A0408-AB53-4E4C-8C5A-6AB71DFF8ADD

Q30398715-5949142D-7A8C-47DF-A625-6F89EEF3BBFD

Q30398715-5C56CE9B-7631-4DF8-BA2D-E57AEA4DF724

Q30398715-62D9D728-775B-497C-A97B-F84F60FE14F9

Q30398715-6A0A81E6-FEC9-46C1-AD36-B70E7B52CF78

Q30398715-7360D046-EA94-44BF-909C-55068DED9E28

Q30398715-8099D377-9EA3-4546-8241-FF0D8D4F5DA5

Q30398715-8B80B6E5-F9A6-4655-B491-4DCED70F15D9

P2860

Q30398715-05D80CA5-C585-4484-8483-59B3E0457C92

Q30398715-1FF56DCA-44EB-49C0-8E50-44BF0DD0E6FC

Q30398715-20D47BFC-A1D2-4064-8236-22F2E19E6962

Q30398715-2210FC7F-207A-4A02-8D8F-CDF6A5EA4B02

Q30398715-27413741-42AD-48F5-B380-0D99A2D1CD97

Q30398715-288F45A6-1C44-471D-9F8D-E447FA2F3DDC

Q30398715-3023F9EB-271C-44B6-A43F-48533B1DF53D

Q30398715-3076711C-9260-4C44-B923-15B2E7F86862

Q30398715-3841C993-E977-4935-B931-F2286B5F47D5

Q30398715-3FF914D5-5C57-4D8F-94AE-7177B9548B51

P304

Q30398715-51FE339F-8861-420A-B95F-B8508B3EDC5D

P31

Q30398715-58E42D84-AE09-4F6A-A6D6-B3EE214D0C53

P356

Q30398715-4CC7DC36-A345-488D-9D06-1291BEDF47E7

P407

Q30398715-863F67BE-01B8-496B-9C69-76706BCE032D

P433

Q30398715-EBC78C94-92EF-4709-9667-E3F1A8F3370D

P478

Q30398715-18BA7C0F-CD4D-42C8-B2F0-167CD7685C0A

P50

Q30398715-45EF7DE6-E829-44C0-8FF1-523FF172963B

Q30398715-D2284B47-A9F9-427C-B070-B00FDB1A5E3F

Q30398715-F98D12B6-5801-484B-9CEA-1A71DC9A8C6F

P577

Q30398715-37D3E0D5-20A7-466C-94B2-59B419524657

P5875

Q30398715-DC7FDE76-97E0-4106-9C75-36C480A20CC0

P698

Q30398715-2B714727-E3D0-4BA8-873F-9822C2C1F51C

P921

Q30398715-6F55307A-39AF-4282-819C-17446C3A9196

P356

P1433

Clinical Infectious Diseases

P1476

Convalescent plasma treatment ...... A (H1N1) 2009 virus infection

@en

P2093

Bone Sf Tang

http://www.w3.org/2001/XMLSchema#string

Candy Cy Lau

http://www.w3.org/2001/XMLSchema#string

Che-Kit Lin

http://www.w3.org/2001/XMLSchema#string

Cheuk-Kwong Lee

http://www.w3.org/2001/XMLSchema#string

Chi-Keung Ching

http://www.w3.org/2001/XMLSchema#string

Chi-Kwan Koo

http://www.w3.org/2001/XMLSchema#string

Chi-Leung Watt

http://www.w3.org/2001/XMLSchema#string

Fu-Loi Chow

http://www.w3.org/2001/XMLSchema#string

Hok-Sum Chan

http://www.w3.org/2001/XMLSchema#string

Iris Ws Li

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?

Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009

The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza

Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza

Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection.

Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis.

Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

Critical care services and 2009 H1N1 influenza in Australia and New Zealand.

Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome.

P304

447-456

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIQ106

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

Kelvin Kai-Wang To

Ivan Fan Ngai Hung

P577

2011-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49767909

http://www.w3.org/2001/XMLSchema#string

P698

21248066

http://www.w3.org/2001/XMLSchema#string

P921